NARCAN Now Covered by Eight Orange Book-Listed Patents

SANTA MONICA, Calif., Dec. 24, 2018 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that its most recently issued U.S. Patent, No. 10,085,937, covering methods of use for the four-milligram (“4 mg”) formulation of NARCAN® Nasal Spray (“NARCAN”) for the treatment of opioid overdose, is now listed in the U.S. Food and Drug Administration (“FDA”) publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.

“We are pleased to further strengthen our intellectual property surrounding NARCAN with the issuance of this patent and Orange Book listing,” said Roger Crystal, M.D., Chief Executive Officer of Opiant.  “We now have eight Orange Book-listed patents for NARCAN, five of which cover the 4 mg formulation.”

U.S. Patent No. 10,085,937 claims nasal spray formulations and methods of treatment covering the 4 mg dose of NARCAN. The patent provides for drug products adapted for nasal delivery via a pre-primed device filled with a pharmaceutical composition containing an opioid receptor antagonist. The patent also provides for methods of treating opioid overdose or its symptoms with the 4 mg formulation of NARCAN. An Orange Book listing requires an Abbreviated New Drug Application applicant seeking FDA approval of a generic version of NARCAN to notify Opiant and its partner, Adapt Pharma Limited, a subsidiary of Emergent Biosolutions Inc., before it can obtain FDA approval. This would be subject to a 30-month stay of marketing approval and potentially longer if such notification occurs and a patent infringement suit is successful.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. National Institute of Drug Abuse, a division of the National Institutes of Health, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant’s first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its commercialization partner, Adapt Pharmaceuticals, now owned by Emergent BioSolutions, Inc.  For more information please visit: www.opiant.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-KT for the transition period August 1 to December 31, 2017 and Form 10-Q for the period ended September 30, 2018, filed with the Securities and Exchange Commission on March 7, 2018 and November 7, 2018, respectively, including under the caption titled “Risk Factors.”  These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACTS:

For Investor Relations:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
(617) 535-7746

For Media Inquiries:
Julie Normart
W2O Group
[email protected]
(415) 946-1087